Relmada Q1 2023 Earnings Report
Key Takeaways
Relmada Therapeutics reported its first quarter 2023 financial results, focusing on the development program of REL-1017 for major depressive disorder. Enrollment is progressing for Study 302, with trial completion anticipated in the first half of 2024, and site selection has been finalized for the new planned Study 304.
Focused on optimizing the potential for success in the late-stage development program of REL-1017 for the adjunctive treatment of major depressive disorder.
The amended protocol for ongoing Study 302 is now being implemented and enrollment is progressing, with trial completion anticipated in the first half of 2024.
Finalized site selection and solidified a rigorous patient eligibility process for the new planned Study 304.
Sufficiently funded to execute plans to reach data readouts from both Phase 3 trials in 2024.
Relmada
Relmada
Forward Guidance
Relmada Therapeutics is focused on the clinical development of REL-1017. The company believes it has identified clinical sites that can better control placebo response and is focused on enrolling appropriate subjects with documented diagnoses and treatment histories. The company anticipates data readouts from both Phase 3 trials in 2024.